SIGA to Host Business Update Call on March 11, 2025 Following Release of Fourth-Quarter and Full Year 2024 Financial Results

Rhea-AI Summary

SIGA Technologies (Nasdaq: SIGA) has scheduled a business update conference call and webcast for March 11, 2025, at 4:30 P.M. ET, following the release of its fourth-quarter and full year 2024 financial results.

The call will feature CEO Diem Nguyen and CFO Daniel Luckshire. Investors can access the call through:

• Domestic dial-in: 1-800-717-1738
• International dial-in: 1-646-307-1865
• Company website: www.siga.com (Investor Relations section)

A two-week replay will be available via domestic (1-844-512-2921) and international (1-412-317-6671) numbers using Conference ID: 1152574. The webcast will be archived in the Investor Relations section.

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 11, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.

Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers.

A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1152574. The archived webcast will be available in the Investor Relations section of the Company's website.

About SIGA
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX^® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit www.siga.com.

Contacts:
Suzanne Harnett sharnett@siga.com
and
Investors	Media
Jennifer Drew-Bear, Edison Group Jdrew-bear@edisongroup.com	Holly Stevens, Berry & Company hstevens@berrypr.com

FAQ

When will SIGA Technologies release its Q4 and full year 2024 financial results?

SIGA will release its Q4 and full year 2024 financial results on March 11, 2025, followed by a business update call at 4:30 P.M. ET.

How can investors access SIGA's Q4 2024 earnings call?

Investors can access the call via domestic (1-800-717-1738) or international (1-646-307-1865) numbers, or through SIGA's website at www.siga.com in the Investor Relations section.

Who will be presenting at SIGA's March 11, 2025 business update call?

CEO Diem Nguyen and CFO Daniel Luckshire will be presenting at SIGA's business update call.

How long will SIGA's Q4 2024 earnings call replay be available?

The call replay will be available for two weeks using Conference ID 1152574, with domestic and international dial-in numbers provided.